Compare Crispr Therapeutics AG (CRSP) vs Domino's Pizza, Inc. (DPZ) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Crispr Therapeutics AG vs Domino's Pizza, Inc. — how do they compare? Crispr Therapeutics AG trades at $50.54 (market cap $4.97B), while Domino's Pizza, Inc. trades at $309.85 (market cap $10.31B). The key difference: Domino's Pizza, Inc. is far larger — about 2.1× Crispr Therapeutics AG's market cap, and Domino's Pizza, Inc. pays a 2.57% dividend while Crispr Therapeutics AG pays none. Which is the better fit depends on your goals.
| CRSP | DPZ | |
|---|---|---|
Market Cap | $4.97B | $10.31B |
Sector | Health | Consumer Cyclical |
52-Week High | $76.78 | $485.53 |
52-Week Low | $44.34 | $282.89 |
Enterprise Value | $3.32B | $15.21B |
Dividend Yield | — | 2.57% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
CRSP trades at $50.63, down 5.1% over 24 hours, amid a bearish technical signal. The company shows deep losses with a net income margin of -56,853.4% in 2025 and negative cash flow from operations. However, analyst consensus remains optimistic with a $74.50 price target, and recent news highlights FDA approval for Casgevy, expanding its gene therapy market.
The outlook hinges on commercial execution of Casgevy and pipeline progress, offering high growth potential in gene editing. Key risks include sustained cash burn, competitive pressures, and regulatory hurdles. Despite current financial challenges, strong analyst buy ratings suggest confidence in long-term value.
Domino's Pizza (DPZ) trades at $309.85, up 3.47% today, with a neutral technical signal and bearish moving averages. The company reported Q1 2026 EPS of $4.13, missing expectations, but maintains strong profitability with a net margin of 11.89%. Recent news includes CEO succession and new product launches, while analyst consensus remains bullish with a $380.31 price target.
DPZ offers steady growth and a 2.66% dividend yield, but faces risks from slowing same-store sales and high debt. The stock's valuation at 17.84x P/E is reasonable, yet competitive pressures and macroeconomic headwinds warrant caution. Upside potential exists if Q2 earnings beat expectations and new leadership reinvigorates growth.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Crispr Therapeutics AG
CRISPR Therapeutics is a gene editing company focused on the development of CRISPR/Cas9-based therapeutics. CRISPR/Cas9 stands for Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9), which is a revolutionary technology for precisely altering specific sequences of genomic DNA. The company is focused on using this technology to treat genetically defined diseases. CRISPR's most advanced pipeline candidate, CTX001, is in collaboration with Vertex Pharmaceuticals and targets sickle cell disease and transfusion-dependent beta-thalassemia, which have high unmet medical needs. The company is progressing additional gene editing programs for immuno-oncology, as well as a stem cell-derived therapy for the treatment of Type 1 diabetes.
Read more on CRSP →About Domino's Pizza, Inc.
Domino's is a restaurant operator and franchiser with nearly 19,000 global stores across more than 90 international markets at the end of 2021. The firm generates revenue through the sales of pizza, wings, salads, and sandwiches at company-owned stores, royalty and marketing contributions from franchise-operated stores, and its network of 25 domestic (and five Canadian) dough manufacturing and supply chain facilities, which centralize purchasing, preparation, and last-mile delivery for the firm's U.S. and Canadian restaurants. With roughly $17.7 billion in 2021 system sales, Domino's is the largest player in the global pizza market, ahead of Pizza Hut, Papa John's, and Little Caesars.
Read more on DPZ →
